Platelet and Coagulation Activation in Myeloproliferative Diseases (MPD), and Relationship to JAK2(V617F) Mutation Status and Clonality
| Autor: | Colin Urquhart, Mark A. Vickers, Isobel Ford, Henry G. Watson, Michael Greaves, Beverley J. Robertson |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
business.industry Immunology Cell Biology Hematology medicine.disease Biochemistry Thrombosis Gastroenterology Thrombin Coagulation hemic and lymphatic diseases Internal medicine medicine Platelet Platelet activation Thrombus Risk factor business Prospective cohort study medicine.drug |
| Zdroj: | Blood. 108:4082-4082 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v108.11.4082.4082 |
| Popis: | Patients with MPD have an increased risk of thrombosis. Previous reports suggest an association between clonality and thrombosis in ET. The contribution of the JAK2 mutation to thrombotic risk is unclear. In our cohort of patients with MPD (n=122) (PRV n = 54, ET n = 64, IMF n= 4), we compared coagulation and platelet activation markers (D-Dimers, thrombin antithrombin complexes (TAT), prothrombin fragments 1+2 (F1+2), soluble E-selectin(sE-selectin) and soluble P-selectin(sP-selectin)) between MPD patients and hypertensive controls. sP-selectin was significantly increased in patients with MPD (p= There was no significant difference in platelet count between JAK2 positive and negative patients (p=0.19). The clonality of the MPD was determined in 54 female patients using an x-chromosome inactivation pattern (XCIP) assay (HUMARA). A significant proportion of “polyclonal” patients, as defined by XCIPs were positive for the JAK2 mutation. We therefore calculated the proportion clonality of samples and found no correlation between proportion clonality and any coagulation or platelet activation marker. Our results show an increase in platelet activation, as determined by sP-selectin levels, in patients with MPD compared to controls. Furthermore, platelet activation was a feature of patients positive for the JAK2 mutation when compared with wild type patients and controls. The role of the JAK2 mutation as a risk factor for thrombosis in MPD is still unclear but our study indicates that the presence of the mutation may be linked to platelet activation in MPD. Whether this translates into a higher clinical thrombosis risk requires further evaluation in a large prospective study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|